Response to the letter by Ghanim et al, “Comment on Gao et al’s ‘A multicenter, randomized, double-blinded, placebo-controlled phase III trial to evaluate efficacy and safety of picankibart in moderate-to-severe plaque psoriasis’”
Response to the letter by Ghanim et al, “Comment on Gao et al’s ‘A multicenter, randomized, double-blinded, placebo-controlled phase III trial to evaluate efficacy and safety of picankibart in moderate-to-severe plaque psoriasis’”. // Journal of the American Academy of Dermatology. – URL: https://www.sciencedirect.com/science/article/pii/S0190962226033025?dgcid=rss_sd_all
Response to the letter by Ghanim et al, “Comment on Gao et al’s ‘A multicenter, randomized, double-blinded, placebo-controlled phase III trial to evaluate efficacy and safety of picankibart in moderate-to-severe plaque psoriasis’”. Journal of the American Academy of Dermatology. https://www.sciencedirect.com/science/article/pii/S0190962226033025?dgcid=rss_sd_all
“Response to the letter by Ghanim et al, “Comment on Gao et al’s ‘A multicenter, randomized, double-blinded, placebo-controlled phase III trial to evaluate efficacy and safety of picankibart in moderate-to-severe plaque psoriasis’”.” Journal of the American Academy of Dermatology.
@article{article117226,
title = {Response to the letter by Ghanim et al, “Comment on Gao et al’s ‘A multicenter, randomized, double-blinded, placebo-controlled phase III trial to evaluate efficacy and safety of picankibart in moderate-to-severe plaque psoriasis’”},
journal = {Journal of the American Academy of Dermatology},
url = {https://www.sciencedirect.com/science/article/pii/S0190962226033025?dgcid=rss_sd_all}
}